Fixed dosing of HER antibodies
The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.
1. An article of manufacture comprising a single dose vial containing a single fixed dose of pertuzumab, wherein the fixed dose is selected from the group consisting of 420 mg and 840 mg of pertuzumab.
2. The article of manufacture of claim 1 further comprising a package insert instructing the user to administer the fixed dose to a cancer patient.
3. The article of manufacture of claim 2 wherein the cancer is selected from the group consisting of ovarian cancer, peritoneal cancer, fallopian tube cancer, metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), prostate cancer, and colorectal cancer.
4. The article of manufacture of claim 1 comprising two vials, wherein a first vial contains a single fixed dose of 840 mg of pertuzumab, and a second vial contains a single fixed dose of 420 mg of pertuzumab.
5. An article of manufacture comprising a container holding a single fixed dose of a HER2 antibody comprising the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively, wherein the fixed dose is selected from the group consisting of 420 mg and 840 mg of the HER2 antibody.
6. The article of manufacture of claim 5 wherein the fixed dose is 420 mg of the HER2 antibody.
7. The article of manufacture of claim 5 wherein the fixed dose is 840 mg of the HER2 antibody.
8. An article of manufacture comprising a 20 cc vial holding a single fixed dose of a HER2 antibody comprising the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively, wherein the fixed dose is 420 mg of the HER2 antibody.
9. The article of manufacture of claim 1 wherein the vial is a 20 cc vial containing a 420 mg fixed dose of the HER2 antibody.